Can I read Management of refractory and resistant CMV: A step forward but more work needed on EtoBox?
Management of refractory and resistant CMV: A step forward but more work needed by Rbab Taha; Atul Humar is a Medicine article available to read on EtoBox.
What is Management of refractory and resistant CMV: A step forward but more work needed about?
EDITORIAL in whom ganciclovir is not a good option? Advantages of letermovir include the relative ease of access to the drug in many (but not all) jurisdictions, as well as its good safety profile. However, in the absence of well-designed controlled trials, its use in this setting should perhaps be limited to those with low viral loads or as secondary prophylaxis once ganciclovir refractory/resistant infection is treated. Other exciting areas to explore include use of combination regimens and variation of dosage. Overall, it is an exciting time in the CMV field. Advances noted above, coupled with emerging data on cell-based therapies, monoclonal antibodies and new types of vaccines all have the potential to quickly increase our armamentarium against what was once the scourge of transplantation. Ultimately, the key beneficiaries will be our patients.
Who reads Management of refractory and resistant CMV: A step forward but more work needed?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Rbab Taha; Atul Humar
- Publisher
- Wiley
- Published
- 2021
- Language
- EN
- Field
- Medicine (Health Sciences)